Results of New Combined Analysis Concludes Patients at Risk for Glaucoma Will Benefit From Risk Assessment Tool
Geschrieben am 15-11-2006 |
Las Vegas, November 15 (ots/PRNewswire) -
- New data confirm a five-year risk assessment tool will help ophthalmologists better predict which patients have an increased risk of developing glaucoma - Analysis finds that patients with elevated intraocular pressure (IOP) - along with other predictive risk factors, such older age (40+) - are at highest risk of progressing to primary open-angle glaucoma (POAG) - Investigator: 'It is critical to continue to evaluate and refine innovative, predictive models in ophthalmic medicine in order to provide the best treatment possible for patients.'
A combined analysis of two landmark clinical glaucoma trials -- the Ocular Hypertension Treatment Study (OHTS) and the European Glaucoma Prevention Study (EGPS) -- confirms the benefit of a five-year risk assessment model to help ophthalmologists better predict which patients have an increased risk of developing glaucoma. Glaucoma is the second leading cause of blindness in the world, affecting approximately 70 million people, and can lead to blindness if left untreated. These new data were presented this week at the annual American Academy of Ophthalmology meeting.
The analysis showed that patients with elevated intraocular pressure (IOP) -- along with other predictive risk factors, such as older age (40+) -- are at highest risk of progressing to primary open-angle glaucoma (POAG). The results are similar to the 2005 risk-assessment model reported by Dr. Robert N. Weinreb and Dr. Felipe A. Medeiros based on findings from the 2002 Ocular Hypertension Treatment Study (OHTS), a five-year National Eye Institute-sponsored trial that found early intervention with IOP-lowering medications could prevent glaucoma in at-risk patients
"It is critical to continue to evaluate and refine innovative, predictive models in ophthalmic medicine in order to provide the best treatment possible for patients," said Dr. Michael Kass. "We hope this tool will become as universally adapted as predictive models used in other therapeutic areas, such as the Framingham Study, which provided a basis for accurate cardiac risk assessment."
"For some time we have known that if we could identify those patients most likely to progress to glaucoma, earlier intervention with effective treatments could help reduce the risk of vision impairment," said Dr. Robert N. Weinreb, director of the Hamilton Glaucoma Center and Distinguished Professor of Ophthalmology at the University of California, San Diego, USA. "This new analysis provides a larger-scale validation of breakthrough findings of the OHTS group and reinforces to clinicians how the tool can be useful in assessing which patients are most at risk."
The OHTS prediction model was tested on patients in the EGPS placebo group and the two study samples from the control (non-treated) arms were pooled to increase precision and generalizability of a five-year predictive model for developing POAG. The OHTS observation group contained 819 patients with a median follow up of every six months for 6.6 years. The EGPS placebo group contained 500 patients with a median follow up of every six months for 4.8 years.
"We know that awareness of these predictors, particularly elevated intraocular pressure, and central corneal thickness, is critical in treating and potentially preventing damage to the optic nerve caused by glaucoma progression," said Professor Stefano Miglior, director of the Department of Ophthalmology, Policlinico di Monza, University of Milan Bicocca, Italy, and Chairman of EGPS. "The large-scale validation, which includes a European patient population for the first time, reinforces the consensus about the importance of informed dialogue between physicians and patients on how often eye examinations are needed and when it might be appropriate to initiate treatment."
The research was supported by grants from Pfizer Inc, the National Eye Institute and the National Center for Minority Health and Health Disparities, National Institutes of Health, the European Commission and Research to Prevent Blindness and Merck Research Laboratories.
Pfizer's current product line includes the most prescribed treatment to lower elevated eye pressure in patients with ocular hypertension (abnormally high eye pressure) or open-angle glaucoma. In collaboration with (OSI) Eyetech, the division also includes a treatment for neovascular age-related macular degeneration.
Web site: http://www.pfizer.com
ots Originaltext: Pfizer Inc. Im Internet recherchierbar: http://www.presseportal.de
Contact: Judy Brooks of Pfizer Inc, +1-212-573-7897; Company News On-Call: Pfizer's press releases are available through PR Newswire's Company News On-Call service on PRN's Web Site. Visit http://www.prnewswire.com/comp/688250.html; Photo: A free corporate logo to accompany this story is available immediately via Wieck Photo Database to any media with telephoto receiver or electronic darkroom, PC or Macintosh, that can accept overhead transmissions. To retrieve a logo, please call +1-972-392-0888; Company News On-Call: http://www.prnewswire.com/comp/688250.html
Kontaktinformationen:
Leider liegen uns zu diesem Artikel keine separaten Kontaktinformationen gespeichert vor.
Am Ende der Pressemitteilung finden Sie meist die Kontaktdaten des Verfassers.
Neu! Bewerten Sie unsere Artikel in der rechten Navigationsleiste und finden
Sie außerdem den meist aufgerufenen Artikel in dieser Rubrik.
Sie suche nach weiteren Pressenachrichten?
Mehr zu diesem Thema finden Sie auf folgender Übersichtsseite. Desweiteren finden Sie dort auch Nachrichten aus anderen Genres.
http://www.bankkaufmann.com/topics.html
Weitere Informationen erhalten Sie per E-Mail unter der Adresse: info@bankkaufmann.com.
@-symbol Internet Media UG (haftungsbeschränkt)
Schulstr. 18
D-91245 Simmelsdorf
E-Mail: media(at)at-symbol.de
40029
weitere Artikel:
- Roland Berger Strategy Consultants: Preise für die erfolgreichsten polnischen Unternehmen Warschau (ots) - Sperrfrist: 15. November 2006, 21:00 Uhr - Roland Berger Strategy Consultants verleiht "Best of European Business Award" zum zweiten Mal an polnische Top-Unternehmen am 15. November - Die Veranstaltung in Polen stellt die sechste Etappe des Wettbewerbs in insgesamt zehn Ländern dar - Die Gewinner des deutschen Wettbewerb werden am 20. November 2006 in Berlin ausgezeichnet - Die europäische Abschlussgala findet am 15. März 2007 in Brüssel statt Roland Berger Strategy Consultants mehr...
- Micrel bringt branchenweit kleinsten und dünnsten 8 MHz 'induktorlosen' Step-down-Regler für mobile Spannungsregler San Jose, Kalifornien, November 15 (ots/PRNewswire) - - Electronica gewährt erste Blicke auf Vorversion von Micrel MIC3385 Micrel Inc., (Nasdaq: MCRL), Branchenführer für IC-Lösungen im Bereich der Ethernet-, Analog- und schneller Breitbandkommunikation, gab heute bekannt, man werde auf der auf der Electronica 2006 in München eine Vorversion des MIC3385, des bisher kleinsten und dünnsten induktorlosen 8 MHz Step-down-Reglers der Branche, zeigen. Der neue, in einem 3 x 3,5 x 0,9 mm grossen MLF-Gehäuse untergebrachte IC ist ideal geeignet mehr...
- MACQUARIE EUROPEAN INFRASTRUCTURE FUND II (MEIF II) TEILT BEGINN DER ANNAHMEFRIST UND VERÖFFENTLICHUNG DES BARÜBERNAHMEANGEBOTS FÜR AKTIEN DER TECHEM AG MIT Frankfurt (ots) - · Barangebot in Höhe von 44 Euro je Techem-Aktie entspricht einer Marktkapitalisierung von 1,1 Milliarden Euro. · Angebot entspricht einer attraktiven Prämie von 18,9 Prozent über dem gewichteten durchschnittlichen inländischen Börsenkurs der letzten drei Monate vor dem 23. Oktober 2006. · Annahmefrist läuft bis zum 21. Dezember 2006, 24.00 Uhr MEZ. · MEIF II bietet als langfristig orientierter Aktionär der Techem AG und ihren Kunden Stabilität, Ressourcen und Expertise. · MEIF II und die Macquarie Gruppe halten derzeit mehr...
- euro adhoc: Precious Woods Holding AG, Zug / Quartals- und Halbjahresbilanz / Precious Woods in den ersten neun Monaten 2006 mit Umsatz- und Gewinnwachstum -------------------------------------------------------------------------------- Ad hoc-Mitteilung übermittelt durch euro adhoc. Für den Inhalt ist der Emittent verantwortlich. -------------------------------------------------------------------------------- 16.11.2006 Precious Woods hat den Umsatz in den ersten neun Monaten von 11,2 Mio. USD im Jahr 2005 auf 32,7 Mio. USD im Jahr 2006 gesteigert, was beinahe einer Verdreifachung entspricht. Darin spiegelt sich die Akquisition der Handelsgesellschaft in Holland und des Holzschnitzel-Kraftwerks mehr...
- euro adhoc: Precious Woods Holding AG, Zug / quarterly or semiannual financial statement / Precious Woods grows turnover and profit in the first nine months of 2006 -------------------------------------------------------------------------------- Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. -------------------------------------------------------------------------------- 16.11.2006 Compared to the same period in the prior year, Precious Woods net turnover in the first nine months almost tripled, from USD 11.2 million in 2005 to USD 32.7 million in 2006. This growth in turnover was driven by the acquisition of the Dutch trading mehr...
|
|
|
Mehr zu dem Thema Finanzen
Der meistgelesene Artikel zu dem Thema:
Century Casinos wurde in Russell 2000 Index aufgenommen
durchschnittliche Punktzahl: 0 Stimmen: 0
|